{"id":"trastuzumab-injectable-product","safety":{"commonSideEffects":[{"rate":"5-27%","effect":"Cardiotoxicity / left ventricular dysfunction"},{"rate":"20-40%","effect":"Infusion reactions"},{"rate":"10-20%","effect":"Nausea"},{"rate":"10-15%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Headache"},{"rate":"10-20%","effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Trastuzumab targets human epidermal growth factor receptor 2 (HER2), a protein overexpressed in certain breast cancers. By binding to HER2, it prevents ligand-induced signaling and recruits immune cells to destroy HER2-positive tumor cells through antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC).","oneSentence":"Trastuzumab is a monoclonal antibody that binds to HER2 receptors on cancer cells, blocking growth signals and triggering immune-mediated cell death.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:39:52.222Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HER2-positive early-stage breast cancer (adjuvant therapy)"},{"name":"HER2-positive metastatic breast cancer"}]},"trialDetails":[{"nctId":"NCT07495930","phase":"PHASE1","title":"A Phase I Study to Compare the Pharmacokinetic Characteristics, Safety, and Immunogenicity of HLX319 and EU-Phesgo®.","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Henlius Biotech","startDate":"2026-04-30","conditions":"Health Adult Subjects","enrollment":24},{"nctId":"NCT07043725","phase":"PHASE3","title":"A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.","startDate":"2025-09-15","conditions":"HER2-positive Breast Cancer","enrollment":544},{"nctId":"NCT07497386","phase":"PHASE2","title":"A Trial of Trastuzumab Rezetecan in Unresectable Locally Recurrent/Metastatic Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2026-04","conditions":"Unresectable Locally Recurrent Breast Cancer, Unresectable Locally Metastatic Breast Cancer","enrollment":150},{"nctId":"NCT04266249","phase":"PHASE2","title":"CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2020-03-13","conditions":"Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8","enrollment":2175},{"nctId":"NCT05132582","phase":"PHASE3","title":"A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Seagen, a wholly owned subsidiary of Pfizer","startDate":"2022-03-07","conditions":"HER2 Positive Breast Cancer","enrollment":654},{"nctId":"NCT03424005","phase":"PHASE1, PHASE2","title":"A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2018-03-30","conditions":"Metastatic Breast Cancer","enrollment":792},{"nctId":"NCT07470203","phase":"","title":"Pyrotinib Combined With Trastuzumab and Pertuzumab for Maintenance Therapy in HER2-Positive Advanced Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2026-03-31","conditions":"HER2-positive Breast Cancer","enrollment":42},{"nctId":"NCT01042379","phase":"PHASE2","title":"I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer","status":"RECRUITING","sponsor":"QuantumLeap Healthcare Collaborative","startDate":"2010-03-01","conditions":"Breast Neoplasms, Breast Cancer, Breast Tumors","enrollment":5000},{"nctId":"NCT05593094","phase":"PHASE1, PHASE2","title":"A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2020-09-03","conditions":"Advanced Solid Tumors, HER2-positive Breast Cancer","enrollment":210},{"nctId":"NCT06100874","phase":"PHASE2","title":"A Single-arm Phase II Trial of SAcituzumab Govitecan and Trastuzumab for HER2+ Metastatic Breast Cancer After Trastuzumab dEruxtEcaN (SATEEN)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Adrienne G. Waks","startDate":"2023-11-20","conditions":"Her 2 Positive Breast Cancer, Breast Cancer Female, Breast Cancer Metastatic","enrollment":28},{"nctId":"NCT05081609","phase":"PHASE1, PHASE2","title":"A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ascendis Pharma Oncology Division A/S","startDate":"2022-01-11","conditions":"Advanced Solid Tumor, Locally Advanced Solid Tumor, Metastatic Solid Tumor","enrollment":320},{"nctId":"NCT06348134","phase":"PHASE2","title":"Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery","status":"RECRUITING","sponsor":"University of Chicago","startDate":"2025-03-18","conditions":"Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, HER2-positive Breast Cancer, Breast Cancer","enrollment":74},{"nctId":"NCT05415215","phase":"PHASE3","title":"A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants With Early or Locally Advanced/Inflammatory HER2-Positive Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2022-07-05","conditions":"Early Breast Cancer, Locally Advanced Breast Cancer, Inflammatory Breast Cancer","enrollment":346},{"nctId":"NCT07386938","phase":"PHASE3","title":"A Study of the Efficacy, Safety and Pharmacokinetics of RPH-051 and Perjeta® in Combination With Trastuzumab and Docetaxel as the 1st Line Therapy in Patients With HER2-positive Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"R-Pharm","startDate":"2024-08-09","conditions":"Locally Advanced Breast Cancer, Metastatic Breast Cancer","enrollment":246},{"nctId":"NCT07047365","phase":"PHASE3","title":"TQB2930 Injection for the Treatment of HER2-positive Advanced Breast Cancer","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.","startDate":"2025-07-25","conditions":"HER2-positive Advanced Breast Cancer","enrollment":416},{"nctId":"NCT07196774","phase":"PHASE3","title":"A Trial of SHR-A1811 Compared to Other Antitumor Therapies as Neoadjuvant Treatments in Early-stage or Locally Advanced HER2-positive Breast Cancer","status":"RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2025-10-23","conditions":"Early-stage or Locally Advanced HER2-positive Breast Cancer","enrollment":740},{"nctId":"NCT06828588","phase":"EARLY_PHASE1","title":"Pilot Study of [68Ga]Ga-ABY-025 Imaging in Patients Undergoing Treatment With HER2-targeted Therapy","status":"NOT_YET_RECRUITING","sponsor":"Vanderbilt-Ingram Cancer Center","startDate":"2026-02","conditions":"Locally Advanced Cancer, Metastatic Cancer, HER2","enrollment":30},{"nctId":"NCT03321045","phase":"EARLY_PHASE1","title":"Positron Emission Tomography (PET) Imaging With Zirconium-89 (89Zr)-Trastuzumab for Prediction of HER2 Targeted Therapy Effectiveness","status":"RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2017-11-21","conditions":"Breast Cancer","enrollment":10},{"nctId":"NCT05296798","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2022-07-18","conditions":"Locally Advanced or Metastatic Breast Cancer","enrollment":922},{"nctId":"NCT05408845","phase":"PHASE2","title":"Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers","status":"RECRUITING","sponsor":"NRG Oncology","startDate":"2023-03-03","conditions":"Metastatic Salivary Gland Carcinoma, Recurrent Salivary Gland Carcinoma, Stage III Major Salivary Gland Cancer AJCC v8","enrollment":146},{"nctId":"NCT03199885","phase":"PHASE3","title":"Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2019-04-05","conditions":"Metastatic Breast Adenocarcinoma, Metastatic HER2-Positive Breast Carcinoma, Recurrent Breast Adenocarcinoma","enrollment":190},{"nctId":"NCT04556773","phase":"PHASE1","title":"A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2020-12-17","conditions":"Metastatic Breast Cancer","enrollment":138},{"nctId":"NCT06245356","phase":"PHASE2","title":"Safety of Trifluridine/Tipiracil in Patients With Dihydropyrimidine Dehydrogenase Deficiency Diagnosed With Metastatic Colorectal or Gastroesophageal Cancer","status":"RECRUITING","sponsor":"UNICANCER","startDate":"2025-03-21","conditions":"Metastatic Colorectal Cancer, Metastatic Gastroesophageal Adenocarcinoma, DPD Deficiency","enrollment":73},{"nctId":"NCT07176702","phase":"PHASE2","title":"A Phase II Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2025-09-30","conditions":"Metastatic PDAC, HER2-positive Status","enrollment":45},{"nctId":"NCT07246317","phase":"PHASE2","title":"Evaluation of Neoadjuvant Therapy With Trastuzumab, Pertuzumab, Docetaxel, and QL1706 in Early or Locally Advanced HER2+ Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2025-12-15","conditions":"Breast Cancer","enrollment":188},{"nctId":"NCT04644237","phase":"PHASE2","title":"Trastuzumab Deruxtecan in Participants With HER2-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2021-03-19","conditions":"Non-Small Cell Lung Cancer","enrollment":152},{"nctId":"NCT05041842","phase":"PHASE2","title":"Treatment With Tucatinib in Patients With an Isolated Brain Progression of a Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNICANCER","startDate":"2021-12-17","conditions":"Metastatic Breast Cancer With a Isolated Brain Progression","enrollment":53},{"nctId":"NCT06680596","phase":"PHASE2","title":"Detecting Tumor DNA in the Blood of HR+/HER2-low Metastatic Breast Cancer Patients to Find Candidates for T-DXd Therapy","status":"ENROLLING_BY_INVITATION","sponsor":"UNICANCER","startDate":"2025-07-30","conditions":"Breast Cancer Metastatic, Breast Cancer Stage IV","enrollment":80},{"nctId":"NCT07086768","phase":"PHASE1","title":"Dose-Escalation and Dose-Expansion Study of BSI-082 Monotherapy and Combined Therapy in Patients With Advanced or Metastatic Solid Tumors","status":"NOT_YET_RECRUITING","sponsor":"Lei Zheng","startDate":"2026-01-01","conditions":"Solid Tumor, Advanced Solid Tumor, Metastatic Solid Tumor","enrollment":57},{"nctId":"NCT07008976","phase":"PHASE3","title":"Clinical Trial of TQB2102 for Injection Versus Trastuzumab Emtansine for Injection in HER2-positive Advanced Breast Cancer","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.","startDate":"2025-07-07","conditions":"Metastatic Breast Cancer","enrollment":246},{"nctId":"NCT06172127","phase":"PHASE2","title":"PHESGO Maintenance After T-DXd Short Induction for HER2+ Unresectable Locally Recurrent or Metastatic Breast Cancer","status":"RECRUITING","sponsor":"MedSIR","startDate":"2024-07-22","conditions":"HER2-positive Breast Cancer","enrollment":165},{"nctId":"NCT06439693","phase":"PHASE2","title":"The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2024-08-08","conditions":"Breast Cancer Female, Breast Cancer, Breast Cancer Metastatic","enrollment":72},{"nctId":"NCT07003074","phase":"PHASE3","title":"A Clinical Study of TQB2102 Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of HER2 Positive Recurrent or Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.","startDate":"2025-06-23","conditions":"Breast Cancer","enrollment":642},{"nctId":"NCT03432741","phase":"PHASE1","title":"Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer","status":"TERMINATED","sponsor":"Mayo Clinic","startDate":"2018-03-27","conditions":"Breast Adenocarcinoma, Metastatic Breast Carcinoma, Recurrent Breast Carcinoma","enrollment":17},{"nctId":"NCT03161353","phase":"PHASE2","title":"Chemotherapy-free Trastuzumab and Pertuzumab in HER2-positive Breast Cancer: FDG-PET Response-adapted Strategy.","status":"ACTIVE_NOT_RECRUITING","sponsor":"MedSIR","startDate":"2017-06-26","conditions":"Breast Cancer","enrollment":377},{"nctId":"NCT05332561","phase":"PHASE2","title":"Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE)","status":"RECRUITING","sponsor":"German Cancer Research Center","startDate":"2023-06-29","conditions":"Early-stage Breast Cancer","enrollment":240},{"nctId":"NCT02488564","phase":"PHASE2","title":"A Study of Liposomal Doxorubicin+Docetaxel+Trastuzumab+Metformin in Operable and Locally Advanced HER2 Positive Breast Cancer","status":"COMPLETED","sponsor":"Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS","startDate":"2014-12-17","conditions":"HER-2 Positive Breast Cancer","enrollment":49},{"nctId":"NCT05414136","phase":"PHASE1","title":"Evaluating the Safety, Tolerability, and Pharmacokinetics of BAT1006","status":"COMPLETED","sponsor":"Bio-Thera Solutions","startDate":"2022-02-10","conditions":"Advanced Solid Tumor","enrollment":37},{"nctId":"NCT04675827","phase":"PHASE2","title":"De-escalation Adjuvant Chemo in HER2+/ER-/node-neg Early BC Patients Who Achieved PCR After Neoadjuvant Chemo & Dual HER2 Blockade","status":"TERMINATED","sponsor":"Jules Bordet Institute","startDate":"2022-01-17","conditions":"HER2-positive Breast Cancer, ER-Negative Breast Cancer, PR-Negative Breast Cancer","enrollment":139},{"nctId":"NCT05824975","phase":"PHASE1, PHASE2","title":"A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)","status":"RECRUITING","sponsor":"GI Innovation, Inc.","startDate":"2023-05-30","conditions":"Advanced Solid Tumor, Metastatic Solid Tumor, Soft Tissue Sarcoma (STS)","enrollment":358},{"nctId":"NCT01957332","phase":"NA","title":"IMaging PAtients for Cancer Drug selecTion - Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Medical Center Groningen","startDate":"2013-08-30","conditions":"Metastatic Breast Cancer","enrollment":217},{"nctId":"NCT05965479","phase":"PHASE2","title":"Developing ctDNA Guided Adjuvant Therapy for Gastrooesophageal Cancer","status":"RECRUITING","sponsor":"University of Southampton","startDate":"2024-04-10","conditions":"Gastrooesophageal Cancer","enrollment":25},{"nctId":"NCT06577376","phase":"PHASE1, PHASE2","title":"A PhaseⅠ/Ⅱ Study of Simmitinib or Irinotecan Liposomes Combined With DP303c in Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Runshi Pharmaceutical Technology Co., Ltd","startDate":"2024-08-26","conditions":"Localized Advanced or Metastatic Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma, Expressing Human Epidermal Growth Factor Receptor-2 (HER-2), Disease Progression After Receiving at Least One and at Most Two Lines of Systemic Treatment in the Past","enrollment":252},{"nctId":"NCT04629846","phase":"PHASE3","title":"Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive and Estrogen Receptor/Progesterone Receptor Negative Breast Cancer to Evaluate the Efficiency and Safety of Treatment With Trastuzumab Plus (+) QL1209/Pertuzumab + Docetaxel.","status":"COMPLETED","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2020-11-23","conditions":"Breast Cancer","enrollment":517},{"nctId":"NCT03272477","phase":"PHASE2","title":"Study to Compare Neoadjuvant Combination of Trastuzumab and Pertuzumab With Concurrent Taxane Chemotherapy or Endocrine Therapy and Quality of Life Assessment Under Adjuvant Therapy in Operable HER2+/HR+ Breast Cancer Patients","status":"COMPLETED","sponsor":"Palleos Healthcare GmbH","startDate":"2017-10-05","conditions":"Breast Neoplasms","enrollment":257},{"nctId":"NCT05135715","phase":"PHASE2","title":"A Study of RC48-ADC in Advanced Melanoma Subjects With HER2 Variant (Mutation, Amplification, Overexpression)","status":"UNKNOWN","sponsor":"RemeGen Co., Ltd.","startDate":"2022-04-19","conditions":"Melanoma, Stage II, HER2-positive, Advanced Melanoma","enrollment":50},{"nctId":"NCT05238831","phase":"EARLY_PHASE1","title":"SMMART Adaptive Clinical Treatment (ACT) Trial","status":"WITHDRAWN","sponsor":"OHSU Knight Cancer Institute","startDate":"2023-01-30","conditions":"Advanced Breast Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Ovarian Carcinoma","enrollment":""},{"nctId":"NCT05203601","phase":"PHASE1","title":"A Phase Ⅰa Clinical Study Exploring Efficacy of SIBP-03 When Treating the Patients With Advanced Malignant Solid Tumors.","status":"COMPLETED","sponsor":"Shanghai Institute Of Biological Products","startDate":"2020-11-26","conditions":"Tumor","enrollment":36},{"nctId":"NCT04714190","phase":"PHASE3","title":"A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression","status":"UNKNOWN","sponsor":"RemeGen Co., Ltd.","startDate":"2021-03-24","conditions":"Gastric Cancer, HER2 Overexpressing Gastric Carcinoma","enrollment":351},{"nctId":"NCT04329429","phase":"PHASE2","title":"A Study of RC48-ADC in Subjects With HER2 Overexpressed Metastatic Biliary Tract Cancer","status":"UNKNOWN","sponsor":"RemeGen Co., Ltd.","startDate":"2020-08-24","conditions":"Biliary Tract Cancer","enrollment":57},{"nctId":"NCT04965519","phase":"PHASE2","title":"A Study of RC48-ADC for the Treatment of HER2-expressing Gynecological Malignancies","status":"UNKNOWN","sponsor":"RemeGen Co., Ltd.","startDate":"2021-12-21","conditions":"Gynecological Malignancy","enrollment":120},{"nctId":"NCT04197687","phase":"PHASE2","title":"TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery","status":"UNKNOWN","sponsor":"Academic and Community Cancer Research United","startDate":"2020-02-20","conditions":"Breast Adenocarcinoma, Stage II Breast Cancer AJCC v6 and v7, Stage IIA Breast Cancer AJCC v6 and v7","enrollment":480},{"nctId":"NCT04073602","phase":"PHASE2","title":"A Study of RC48-ADC in Subjects With HER2-negative Locally Advanced or Metastatic Urothelial Cancer","status":"COMPLETED","sponsor":"RemeGen Co., Ltd.","startDate":"2019-08-19","conditions":"Urothelial Carcinoma","enrollment":19},{"nctId":"NCT03809013","phase":"PHASE2","title":"A Open-label, Single-arm, Multicenter, Phase II Study of RC48-ADC to Evaluate the Efficacy and Safety of Subjects With HER2 Overexpressing Locally Advanced or Metastatic Urothelial Cancer","status":"COMPLETED","sponsor":"RemeGen Co., Ltd.","startDate":"2019-01-07","conditions":"Urothelial Carcinoma","enrollment":64},{"nctId":"NCT03953833","phase":"PHASE1","title":"B003 in Patients With HER2-positive Recurrent or Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Shanghai Pharmaceuticals Holding Co., Ltd","startDate":"2019-04-01","conditions":"HER2-positive Breast Cancer","enrollment":30},{"nctId":"NCT05755048","phase":"PHASE3","title":"FS-1502 Versus T-DM1 for HER2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer","status":"UNKNOWN","sponsor":"Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.","startDate":"2023-03-28","conditions":"Breast Cancer","enrollment":314},{"nctId":"NCT05983094","phase":"PHASE2","title":"Study of Utidelone Based Neoadjuvant Treatment on Early High-risk or Locally Advanced Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2023-09-01","conditions":"Breast Cancer, Neoadjuvant Therapy","enrollment":181},{"nctId":"NCT05898373","phase":"PHASE1, PHASE2","title":"Vedicitumomab Alone or in Combination for the Treatment of Locally Advanced or Metastatic SDC","status":"NOT_YET_RECRUITING","sponsor":"Peking Union Medical College","startDate":"2023-06-07","conditions":"Salivary Gland Cancer","enrollment":120},{"nctId":"NCT01875367","phase":"PHASE3","title":"Phase III to Evaluate Patient´s Preference of Subcutaneous Trastuzumab vs Intravenous in HER2+ Advanced Breast Cancer","status":"COMPLETED","sponsor":"Spanish Breast Cancer Research Group","startDate":"2013-09-18","conditions":"Breast Cancer","enrollment":166},{"nctId":"NCT04382352","phase":"PHASE1","title":"B002 in Patients With HER2-positive Breast Cancer","status":"COMPLETED","sponsor":"Shanghai Pharmaceuticals Holding Co., Ltd","startDate":"2019-05-28","conditions":"Recurrent Breast Cancer, Metastatic Breast Cancer","enrollment":23},{"nctId":"NCT04924699","phase":"PHASE2, PHASE3","title":"A Study of MRG002 in the Treatment of Patients With HER2-positive Unresectable Locally Advanced or Metastatic Breast Cancer","status":"UNKNOWN","sponsor":"Shanghai Miracogen Inc.","startDate":"2021-06-30","conditions":"Advanced Breast Cancer, Metastatic Breast Cancer","enrollment":350},{"nctId":"NCT05765357","phase":"PHASE1","title":"Clinical Study to Compare the Pharmacokinetics and Safety of Trastuzumab for Injection With Herceptin® in Healthy Male Volunteers","status":"COMPLETED","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2017-07-16","conditions":"Metastatic Breast Cancer, Metastatic Gastric Cancer","enrollment":89},{"nctId":"NCT05301010","phase":"PHASE3","title":"Clinical Trial to Assess Efficacy and Safety of NNG-TMAB (Trastuzumab) on Recurrent or Metastatic Breast Cancer Patients","status":"COMPLETED","sponsor":"Nanogen Pharmaceutical Biotechnology Joint Stock Company","startDate":"2018-02-02","conditions":"Breast Cancer Metastatic, Breast Cancer Recurrent, Breast Cancer Female","enrollment":128},{"nctId":"NCT05656079","phase":"NA","title":"To Evaluate the Cardiac Safety of Pegylated Liposomal Doxorubicin Concurrently Plus Trastuzumab and Pertuzumab in the Adjuvant Setting for Early-stage HER-2-positive Breast Cancer: a Multicenter, Randomized Controlled Clinical Study","status":"UNKNOWN","sponsor":"Shanghai Pudong Hospital","startDate":"2021-07-01","conditions":"Breast Cancer","enrollment":204},{"nctId":"NCT05560308","phase":"NA","title":"Phase II Clinical Study of T-DM1 and Pyrotinib Maleate in Patients With HER2-positive Metastatic Breast Cancer Who Had Progressed on TKI Therapy","status":"UNKNOWN","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2022-09-30","conditions":"HER2+ Advanced Breast Cancer Patients Progressing on TKI Therapy","enrollment":50},{"nctId":"NCT05420454","phase":"PHASE4","title":"A Study for the Neoadjuvant Treatment of Breast Cancer","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2022-07-10","conditions":"Breast Cancer","enrollment":1576},{"nctId":"NCT05420467","phase":"PHASE4","title":"A Study for the Adjuvant Treatment of Breast Cancer","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2022-07-10","conditions":"Breast Cancer","enrollment":2413},{"nctId":"NCT05301530","phase":"PHASE1","title":"Clinical Trial to Assess Pharmacokinetic Parameters and Safety of NNG-TMAB (Trastuzumab) on Recurrent or Metastatic Breast Cancer Patients.","status":"COMPLETED","sponsor":"Nanogen Pharmaceutical Biotechnology Joint Stock Company","startDate":"2019-05-27","conditions":"Breast Cancer Metastatic, Breast Cancer Female, Breast Cancer Recurrent","enrollment":50},{"nctId":"NCT03556345","phase":"PHASE2","title":"A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer Subjects With the Overexpression of HER2","status":"COMPLETED","sponsor":"RemeGen Co., Ltd.","startDate":"2018-07-10","conditions":"Gastric Cancer, HER2 Overexpressing Gastric Carcinoma","enrollment":127},{"nctId":"NCT04296942","phase":"PHASE1","title":"BN-Brachyury, Entinostat, Adotrastuzumab Emtansine and M7824 in Advanced Stage Breast Cancer (BrEAsT)","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2021-05-04","conditions":"Breast Cancer, Triple Negative Breast Cancer, HER2+ Breast Cancer","enrollment":1},{"nctId":"NCT01847001","phase":"PHASE2","title":"Study of Propranolol in Newly Diagnosed Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy","status":"COMPLETED","sponsor":"Columbia University","startDate":"2012-10","conditions":"Locally Advanced Malignant Neoplasm, Breast Cancer","enrollment":10},{"nctId":"NCT04189211","phase":"PHASE1","title":"A Clinical Trial of BAT8001 on Safety, Tolerability and Pharmacokinetics for Patients","status":"UNKNOWN","sponsor":"Bio-Thera Solutions","startDate":"2017-03-07","conditions":"HER2-Positive Solid Tumors","enrollment":30},{"nctId":"NCT04185649","phase":"PHASE3","title":"The Efficacy and Safety of BAT8001 Injection for the Treatment of HER2-positive Advanced Breast Cancer","status":"UNKNOWN","sponsor":"Bio-Thera Solutions","startDate":"2018-07-01","conditions":"HER2-positive Advanced Breast Cancer","enrollment":410},{"nctId":"NCT00140140","phase":"PHASE1, PHASE2","title":"A Phase I/II Study of ABI-007 (Abraxane®, Nab®-Paclitaxel)and Vinorelbine in Patients With Stage IV (Metastatic) Breast Cancer","status":"TERMINATED","sponsor":"Celgene","startDate":"2005-08","conditions":"Stage IV (Metastatic) Breast Cancer","enrollment":16},{"nctId":"NCT03507166","phase":"PHASE2","title":"A Phase II Study of RC48-ADC in Subjects With HER2 Positive Metastatic or Unresectable Urothelial Cancer","status":"COMPLETED","sponsor":"RemeGen Co., Ltd.","startDate":"2017-12-28","conditions":"Urothelial Carcinoma, Advanced Cancer","enrollment":43},{"nctId":"NCT03925233","phase":"","title":"Breast Cancer Treatment Based on Organ-like Culture","status":"UNKNOWN","sponsor":"Xijing Hospital","startDate":"2019-01-02","conditions":"Breast Cancer Organoids","enrollment":300},{"nctId":"NCT03203616","phase":"PHASE2","title":"Kadcyla In pAtients With bRAin Metastasis","status":"WITHDRAWN","sponsor":"Jules Bordet Institute","startDate":"2018-02-23","conditions":"Metastatic HER2-positive Breast Cancer With Brain Metastasis","enrollment":""},{"nctId":"NCT00266110","phase":"PHASE2","title":"Vaccine Therapy, Trastuzumab, and Vinorelbine in Treating Patients With Locally Recurrent or Metastatic Breast Cancer","status":"COMPLETED","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2005-12","conditions":"Breast Cancer","enrollment":17},{"nctId":"NCT02738970","phase":"PHASE1","title":"A Dose-Finding Study of Pertuzumab (Perjeta) in Combination With Trastuzumab (Herceptin) in Healthy Male Participants and Women With Early Breast Cancer (EBC)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2016-06-23","conditions":"Early Breast Cancer","enrollment":88},{"nctId":"NCT03085368","phase":"PHASE2, PHASE3","title":"A Randomized Controlled Trial of HER-2 Positive Breast Cancer Patients Treated With Lapatinib vs Herceptin","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2017-03-01","conditions":"HER2-positive Breast Cancer","enrollment":482},{"nctId":"NCT02735798","phase":"EARLY_PHASE1","title":"64-Cu Labeled Brain PET/MRI for MM-302 in Advanced HER2+ Cancers With Brain Mets","status":"WITHDRAWN","sponsor":"Pamela Munster","startDate":"2016-04","conditions":"Brain Metastases, Documented Her2 Overexpression, Advanced Solid Tumor","enrollment":""},{"nctId":"NCT02658461","phase":"","title":"An Observational Time and Motion Study of Trastuzumab Subcutaneous (SC) and Intravenous (IV) Formulations in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (EBC)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2012-02","conditions":"Breast Cancer","enrollment":36},{"nctId":"NCT01928615","phase":"PHASE2","title":"A Study of Subcutaneously Administered Herceptin (Trastuzumab) in Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2013-09","conditions":"Breast Cancer","enrollment":2},{"nctId":"NCT00795678","phase":"","title":"Chemotherapeutic Agents in Brain/Breast","status":"COMPLETED","sponsor":"Case Comprehensive Cancer Center","startDate":"2008-09","conditions":"Breast Cancer, Metastatic Cancer","enrollment":10},{"nctId":"NCT01428414","phase":"PHASE2","title":"Efficacy and Safety Study of Trastuzumab and Paclitaxel Based Regimens to Treat HER2-positive Breast Cancer","status":"UNKNOWN","sponsor":"Zhimin Shao","startDate":"2011-08","conditions":"HER-2 Positive Breast Cancer","enrollment":100}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Herceptin"],"phase":"phase_3","status":"active","brandName":"Trastuzumab Injectable Product","genericName":"Trastuzumab Injectable Product","companyName":"Spanish Breast Cancer Research Group","companyId":"spanish-breast-cancer-research-group","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Trastuzumab is a monoclonal antibody that binds to HER2 receptors on cancer cells, blocking growth signals and triggering immune-mediated cell death. Used for HER2-positive early-stage breast cancer (adjuvant therapy), HER2-positive metastatic breast cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}